A recent post-hoc analysis from a phase 2 study in MDS [59] and oligoblastic AML (20–30% blasts) patients refractory to hypomethylating agents (HMAs) demonstrated patients with the canonical splicing factor mutation in SF3B1 responding significantly better to selinexor. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.